BOULDER, Colo. - SomaLogic, Inc. (NASDAQ: SLGC), a proteomics technology firm, has received approval from its stockholders for a transaction with Standard BioTools Inc. (NASDAQ: LAB). This approval, based on a preliminary vote count from a Special Meeting held on Thursday, marks a significant step towards the merger aimed at creating a diversified leader in the life sciences tools sector.
The SomaLogic Board of Directors expressed gratitude for the stockholder support, which they believe will enable the realization of substantial value from SomaLogic's platform and offer an accelerated path to profitability. The merger, expected to close today, is seen as a strategic move to bolster the companies' positions in the market by leveraging their combined technologies and expertise to advance human health research.
The final voting results of the Special Meeting will be filed with the U.S. Securities and Exchange Commission shortly, as per regulatory requirements.
SomaLogic, known for its capabilities in protein measurement and analysis, supports a range of clients in the pharmaceutical industry, as well as academic and contract research organizations.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.